SK132797A3 - Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis - Google Patents

Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis Download PDF

Info

Publication number: SK132797A3
Authority: SK; Slovakia
Prior art keywords: virus; adenovirus; gax; gene; cell
Prior art date: 1995-03-31

Application number

SK1327-97A

Other languages

English (en)

Slovak (sk)

Inventor

Didier Branellec

Kenneth Walsh

Jeffrey M Isner

Patrice Denefle

Original Assignee

Univ Case Western Reserve

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-31

Filing date

1996-03-28

Publication date

1998-07-08

1996-03-28 Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve

1998-07-08 Publication of SK132797A3 publication Critical patent/SK132797A3/sk

Links

208000037803 restenosis Diseases 0.000 title abstract description 13
230000003463 hyperproliferative effect Effects 0.000 title description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 8
239000013603 viral vector Substances 0.000 title description 4
108090000623 proteins and genes Proteins 0.000 abstract description 54
241000700605 Viruses Species 0.000 abstract description 34
102000004169 proteins and genes Human genes 0.000 abstract description 13
230000001225 therapeutic effect Effects 0.000 abstract description 7
230000002950 deficient Effects 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 82
241000701161 unidentified adenovirus Species 0.000 description 69
239000013612 plasmid Substances 0.000 description 43
101150029117 meox2 gene Proteins 0.000 description 32
239000013598 vector Substances 0.000 description 31
238000011282 treatment Methods 0.000 description 30
238000000034 method Methods 0.000 description 29
210000004509 vascular smooth muscle cell Anatomy 0.000 description 28
239000012634 fragment Substances 0.000 description 19
230000014509 gene expression Effects 0.000 description 17
241001135569 Human adenovirus 5 Species 0.000 description 13
230000000694 effects Effects 0.000 description 13
230000035755 proliferation Effects 0.000 description 11
239000002299 complementary DNA Substances 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
238000010276 construction Methods 0.000 description 9
239000000243 solution Substances 0.000 description 9
108020004414 DNA Proteins 0.000 description 8
239000000203 mixture Substances 0.000 description 8
238000012546 transfer Methods 0.000 description 8
241000700159 Rattus Species 0.000 description 7
201000010099 disease Diseases 0.000 description 7
241001430294 unidentified retrovirus Species 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
239000000017 hydrogel Substances 0.000 description 6
238000010166 immunofluorescence Methods 0.000 description 6
239000002609 medium Substances 0.000 description 6
108091026890 Coding region Proteins 0.000 description 5
102000004594 DNA Polymerase I Human genes 0.000 description 5
108010017826 DNA Polymerase I Proteins 0.000 description 5
108010076504 Protein Sorting Signals Proteins 0.000 description 5
101100022881 Rattus norvegicus Meox2 gene Proteins 0.000 description 5
210000000709 aorta Anatomy 0.000 description 5
238000012217 deletion Methods 0.000 description 5
230000037430 deletion Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000012894 fetal calf serum Substances 0.000 description 5
230000012010 growth Effects 0.000 description 5
238000002744 homologous recombination Methods 0.000 description 5
230000006801 homologous recombination Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000007170 pathology Effects 0.000 description 5
230000002792 vascular Effects 0.000 description 5
241000701022 Cytomegalovirus Species 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
210000000234 capsid Anatomy 0.000 description 4
230000022131 cell cycle Effects 0.000 description 4
230000006870 function Effects 0.000 description 4
230000003902 lesion Effects 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
108010085238 Actins Proteins 0.000 description 3
102000007469 Actins Human genes 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
101100348341 Caenorhabditis elegans gas-1 gene Proteins 0.000 description 3
102000029816 Collagenase Human genes 0.000 description 3
108060005980 Collagenase Proteins 0.000 description 3
230000006820 DNA synthesis Effects 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108700005087 Homeobox Genes Proteins 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
238000002399 angioplasty Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
108010005774 beta-Galactosidase Proteins 0.000 description 3
210000001715 carotid artery Anatomy 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
229960002424 collagenase Drugs 0.000 description 3
230000006378 damage Effects 0.000 description 3
108700004026 gag Genes Proteins 0.000 description 3
239000007789 gas Substances 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
230000010076 replication Effects 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000035899 viability Effects 0.000 description 3
229920000936 Agarose Polymers 0.000 description 2
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
239000002126 C01EB10 - Adenosine Substances 0.000 description 2
241000282465 Canis Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
208000034827 Neointima Diseases 0.000 description 2
241000713896 Spleen necrosis virus Species 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
229960005305 adenosine Drugs 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
229950004398 broxuridine Drugs 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000002900 effect on cell Effects 0.000 description 2
108700004025 env Genes Proteins 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
101150036170 gas-1 gene Proteins 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
239000002502 liposome Substances 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
210000004026 tunica intima Anatomy 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
238000001262 western blot Methods 0.000 description 2
OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
HZLHRDBTVSZCBS-UVJJDBRNSA-N 4-[(e)-(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline;hydrochloride Chemical compound Cl.C1=CC(=N)C(C)=C\C1=C(C=1C=C(C)C(N)=CC=1)/C1=CC=C(N)C=C1 HZLHRDBTVSZCBS-UVJJDBRNSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
241001212038 Arcola Species 0.000 description 1
241001470561 Arracacha virus V Species 0.000 description 1
PLNJUJGNLDSFOP-UWJYBYFXSA-N Asp-Tyr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PLNJUJGNLDSFOP-UWJYBYFXSA-N 0.000 description 1
QPDUWAUSSWGJSB-NGZCFLSTSA-N Asp-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N QPDUWAUSSWGJSB-NGZCFLSTSA-N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
101150044789 Cap gene Proteins 0.000 description 1
102100038909 Caveolin-2 Human genes 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
230000005778 DNA damage Effects 0.000 description 1
231100000277 DNA damage Toxicity 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
102100036912 Desmin Human genes 0.000 description 1
108010044052 Desmin Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
230000010190 G1 phase Effects 0.000 description 1
108091092584 GDNA Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
108010048671 Homeodomain Proteins Proteins 0.000 description 1
102000009331 Homeodomain Proteins Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
241000713862 Moloney murine sarcoma virus Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101100447658 Mus musculus Gas1 gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
241001112090 Pseudovirus Species 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
TZXFLDNBYYGLKA-BZSNNMDCSA-N Tyr-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 TZXFLDNBYYGLKA-BZSNNMDCSA-N 0.000 description 1
206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
102000013127 Vimentin Human genes 0.000 description 1
108010065472 Vimentin Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000004219 arterial function Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
238000010293 colony formation assay Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
210000005045 desmin Anatomy 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000000431 effect on proliferation Effects 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000009144 enzymatic modification Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
239000000835 fiber Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
101150098622 gag gene Proteins 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
230000001632 homeopathic effect Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
235000015250 liver sausages Nutrition 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
230000008747 mitogenic response Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
230000003562 morphometric effect Effects 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
108700024542 myc Genes Proteins 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
-1 neurofilaments Proteins 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
229920001992 poloxamer 407 Polymers 0.000 description 1
229940044476 poloxamer 407 Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000000751 protein extraction Methods 0.000 description 1
230000026447 protein localization Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
101150066583 rep gene Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
108090000064 retinoic acid receptors Proteins 0.000 description 1
102000003702 retinoic acid receptors Human genes 0.000 description 1
238000012552 review Methods 0.000 description 1
239000007320 rich medium Substances 0.000 description 1
102200085102 rs387906955 Human genes 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000009738 saturating Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
108020003113 steroid hormone receptors Proteins 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
101150003509 tag gene Proteins 0.000 description 1
230000008719 thickening Effects 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
231100000216 vascular lesion Toxicity 0.000 description 1
230000006439 vascular pathology Effects 0.000 description 1
210000005048 vimentin Anatomy 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Biotechnology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

SK1327-97A 1995-03-31 1996-03-28 Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis SK132797A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9504234A FR2732357B1 (fr)	1995-03-31	1995-03-31	Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
PCT/US1996/004493 WO1996030385A1 (fr)	1995-03-31	1996-03-28	Vecteurs viraux et leur utilisation pour traiter des maladies hyperproliferatives, en particulier, la restenose

Publications (1)

Publication Number	Publication Date
SK132797A3 true SK132797A3 (en)	1998-07-08

Family

ID=9477928

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1327-97A SK132797A3 (en)	1995-03-31	1996-03-28	Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis

Country Status (16)

Country	Link
US (2)	US5851521A (fr)
EP (1)	EP0817791A4 (fr)
JP (1)	JPH11503314A (fr)
KR (1)	KR19980703454A (fr)
CN (1)	CN1190402A (fr)
AP (1)	AP1011A (fr)
AU (1)	AU701345B2 (fr)
BR (1)	BR9608449A (fr)
CA (1)	CA2216878A1 (fr)
CZ (1)	CZ308897A3 (fr)
FR (1)	FR2732357B1 (fr)
HU (1)	HUP9801767A3 (fr)
OA (1)	OA10516A (fr)
SI (1)	SI9620059A (fr)
SK (1)	SK132797A3 (fr)
WO (1)	WO1996030385A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5856121A (en) *	1994-02-24	1999-01-05	Case Western Reserve University	Growth arrest homebox gene
US7727761B2 (en) *	1995-08-01	2010-06-01	Vegenics Limited	Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
FR2740344B1 (fr) *	1995-10-31	1997-11-21	Rhone Poulenc Rorer Sa	Application de la proteine gax au traitement de cancers
FR2754822B1 (fr) *	1996-10-18	1998-11-27	Rhone Poulenc Rorer Sa	Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations
US6335010B1 (en) *	1996-11-08	2002-01-01	University Of California At San Diego	Gene therapy in coronary angioplasty and bypass
AU3347000A (en)	1999-01-19	2000-08-01	Children's Hospital Of Philadelphia, The	Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
DE60141567D1 (de) *	2000-01-25	2010-04-29	Edwards Lifesciences Corp	Freisetzungssysteme zur behandlung von restenose und anastomotischer intimaler hyperplasie
AU2001239884B2 (en) *	2000-02-25	2006-08-10	Vegenics Limited	Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
US20030100889A1 (en) *	2001-07-05	2003-05-29	Nicolas Duverger	Method of administration of a gene of interest to a vascular tissue
US20030180936A1 (en) *	2002-03-15	2003-09-25	Memarzadeh Bahram Eric	Method for the purification, production and formulation of oncolytic adenoviruses
US20040220656A1 (en) *	2003-04-30	2004-11-04	Epstein Samuel J.	Coated medical devices and methods of making the same
US20080215137A1 (en) *	2003-04-30	2008-09-04	Boston Scientific Scimed, Inc.	Therapeutic driving layer for a medical device
NZ545871A (en) *	2003-09-12	2010-04-30	Vertex Pharma	Animal model for protease activity and liver damage
WO2005087808A2 (fr) *	2004-03-05	2005-09-22	Ludwig Institute For Cancer Research	Matieres et procedes de constructions de liaison de facteurs de croissance
US7582442B2 (en) *	2004-03-16	2009-09-01	The Regents Of The University Of Michigan	Methods and compositions for using aleveolar macrophage phospholipase A2
US7319015B2 (en) *	2004-03-16	2008-01-15	The Regents Of The University Of Michigan	Methods and compositions for using alveolar macrophage phospholipase A2
GB0416487D0 (en)	2004-07-23	2004-08-25	Isis Innovation	Modified virus
US20090233986A1 (en) *	2004-07-27	2009-09-17	Mount Sinai School Of Medicine	Methods and compositions for using sax2
FI20050753A7 (fi)	2004-09-03	2006-03-04	Licentia Oy	Uudet peptidit
WO2006101629A2 (fr) *	2005-02-17	2006-09-28	Vertex Pharmaceuticals Incorporated	Variant d'epissage d'une sous-unite alpha de proteine type iii de canal sodique
KR100747646B1 (ko)	2005-02-25	2007-08-08	연세대학교 산학협력단	데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
ES2363758T3 (es)	2005-08-15	2011-08-16	Vegenics Pty Ltd	Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
US7972813B2 (en) *	2005-09-30	2011-07-05	Vertex Pharmaceuticals Incorporated	Tetrodotoxin-resistant sodium channel alpha subunit
US20080200408A1 (en) *	2005-09-30	2008-08-21	Mccormack Kenneth	Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
DE602005023550D1 (de)	2005-12-14	2010-10-21	Licentia Ltd	Verwendungen eines neurotrophischen Faktors
WO2007089780A2 (fr) *	2006-01-30	2007-08-09	Licentia, Ltd.	Matériaux de thérapie gènique à tyrosine kinase bmx/etk et méthodes
US8114399B2 (en)	2006-05-17	2012-02-14	Ludwig Institute For Cancer Research	Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
FI20070808A0 (fi)	2007-10-25	2007-10-25	Mart Saarma	GDNF:n silmukointivariantit ja niiden käytöt
CN101952436B (zh)	2008-01-09	2013-03-13	建国大学校产学协力团	基于杆状病毒的疫苗
US20090196854A1 (en) *	2008-02-04	2009-08-06	Kytos Biosystems S.A.	Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
FI20080326A0 (fi)	2008-04-30	2008-04-30	Licentia Oy	Neurotroofinen tekijä MANF ja sen käytöt
EP2318036B1 (fr)	2008-06-30	2015-06-03	The Regents of the University of Michigan	Activité phospholipase a2 lysosomale (lpla2) en tant que cible diagnostique et thérapeutique pour identifier et traiter le lupus érythémateux disséminé
EP2496268A4 (fr)	2009-11-06	2013-06-19	Univ Chung Ang Ind	Systèmes de délivrance de gènes à base de nanoparticules
KR101232123B1 (ko)	2010-10-08	2013-02-12	연세대학교 산학협력단	재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
EP2710037B1 (fr)	2011-05-19	2019-07-31	The Regents of The University of Michigan	Agents se liant à l'intégrine alpha-2 et leur utilisation pour inhiber la prolifération des cellules cancéreuses
US9404090B2 (en)	2011-11-24	2016-08-02	Viromed Co., Ltd.	Adenovirus producing novel cell line and the use thereof
US9365496B2 (en)	2011-11-30	2016-06-14	Ludwig Institute For Cancer Research	iNKT cell modulators and methods of using the same
GB201120860D0 (en)	2011-12-05	2012-01-18	Cambridge Entpr Ltd	Cancer immunotherapy
WO2013184209A1 (fr)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif destiné à être utilisé dans des méthodes de traitement de sujets atteints d'une maladie neurodégénérative
RS57789B1 (sr)	2012-09-06	2018-12-31	Univ Chicago	Antisens polinukleotidi za indukovanje preskakanja egzona i postupci lečenja distrofija
KR101429696B1 (ko)	2012-11-21	2014-08-13	국립암센터	안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
MY170528A (en)	2013-02-18	2019-08-09	Vegenics Pty Ltd	Vegfr-3 ligand binding molecules and uses thereof
WO2014191630A2 (fr)	2013-05-28	2014-12-04	Helsingin Yliopisto	Modèle animal non humain codant pour un gène manf non fonctionnel
PT3283500T (pt)	2015-04-08	2021-01-28	Univ Chicago	Composições e métodos para corrigir distrofia muscular das cinturas tipo 2c com utilização de salto do exão
CN108289920A (zh)	2015-10-12	2018-07-17	汉阳大学校产学协力团	用于基因转移和基因治疗的腺病毒复合物
US10626414B2 (en)	2016-09-20	2020-04-21	Boehringer Ingelheim Vetmedica Gmbh	Swine influenza vaccine
UY37405A (es)	2016-09-20	2018-03-23	Boehringer Ingelheim Vetmedica Gmbh	Vectores de adenovirus canino
WO2018054840A1 (fr)	2016-09-20	2018-03-29	Boehringer Ingelheim Vetmedica Gmbh	Nouveaux promoteurs
AR109539A1 (es)	2016-09-20	2018-12-19	Boehringer Ingelheim Vetmedica Gmbh	Sitio de inserción orf70 de ehv
WO2019117632A1 (fr)	2017-12-13	2019-06-20	한양대학교 산학협력단	Adénovirus recombinants et cellules souches les comprenant
EP3802851A4 (fr)	2018-06-11	2022-03-30	University of Florida Research Foundation, Inc.	Matériaux et procédés de traitement de troubles et de cancer liés au stress
WO2024228167A1 (fr)	2023-05-03	2024-11-07	Iox Therapeutics Inc.	Compositions liposomales de modulateur de cellules inkt et procédés d'utilisation
WO2025113643A1 (fr)	2023-12-01	2025-06-05	Gilead Sciences Inc.	Protéine de fusion anti-fap-light et utilisation associée
WO2025259871A1 (fr)	2024-06-14	2025-12-18	Gilead Sciences, Inc.	Anticorps anti-ccr8 et leurs utilisations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8424757D0 (en) *	1984-10-01	1984-11-07	Pasteur Institut	Retroviral vector
FR2573436B1 (fr) *	1984-11-20	1989-02-17	Pasteur Institut	Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US4797368A (en) *	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US5139941A (en) *	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US4861719A (en) *	1986-04-25	1989-08-29	Fred Hutchinson Cancer Research Center	DNA constructs for retrovirus packaging cell lines
JP3082204B2 (ja) *	1988-09-01	2000-08-28	ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ	両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5585362A (en) *	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
CA2039921A1 (fr) *	1990-04-16	1991-10-17	Xandra O. Breakefield	Transfert et expression de la sequence d'adn dans les cellules du systeme nerveux central a l'aide de mutants du virus de l'herpes, avec deletions chez les genes en vue de repliquer le virus
WO1991018088A1 (fr) *	1990-05-23	1991-11-28	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Vecteurs eucaryotiques a base de virus adeno-associes (aav)
US5173414A (en) *	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
US5252479A (en) *	1991-11-08	1993-10-12	Research Corporation Technologies, Inc.	Safe vector for gene therapy
EP1321526A3 (fr) *	1992-11-18	2003-07-02	Arch Development Corporation	Transfert de gènes au muscle lisse cardiaque et musculaire au moyen d'un Adenovirus
JPH08503855A (ja) *	1992-12-03	1996-04-30	ジェンザイム・コーポレイション	嚢胞性線維症に対する遺伝子治療
FR2705361B1 (fr) *	1993-05-18	1995-08-04	Centre Nat Rech Scient	Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) *	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
DE69435108D1 (de) *	1993-07-13	2008-08-14	Centelion	Defekte adenovirus-vektoren und deren verwendung in der gentherapie
US5856121A (en) *	1994-02-24	1999-01-05	Case Western Reserve University	Growth arrest homebox gene

1995
- 1995-03-31 FR FR9504234A patent/FR2732357B1/fr not_active Expired - Fee Related
1996
- 1996-03-28 BR BR9608449-9A patent/BR9608449A/pt not_active Application Discontinuation
- 1996-03-28 SK SK1327-97A patent/SK132797A3/sk unknown
- 1996-03-28 CN CN96193929A patent/CN1190402A/zh active Pending
- 1996-03-28 AU AU55315/96A patent/AU701345B2/en not_active Ceased
- 1996-03-28 WO PCT/US1996/004493 patent/WO1996030385A1/fr not_active Ceased
- 1996-03-28 CA CA002216878A patent/CA2216878A1/fr not_active Abandoned
- 1996-03-28 CZ CZ973088A patent/CZ308897A3/cs unknown
- 1996-03-28 SI SI9620059A patent/SI9620059A/sl not_active IP Right Cessation
- 1996-03-28 JP JP8529747A patent/JPH11503314A/ja not_active Ceased
- 1996-03-28 EP EP96912530A patent/EP0817791A4/fr not_active Withdrawn
- 1996-03-28 AP APAP/P/1997/001117A patent/AP1011A/en active
- 1996-03-28 HU HU9801767A patent/HUP9801767A3/hu unknown
- 1996-03-28 KR KR1019970706858A patent/KR19980703454A/ko not_active Ceased
- 1996-09-30 US US08/723,726 patent/US5851521A/en not_active Ceased
1997
- 1997-09-29 OA OA70089A patent/OA10516A/en unknown
2000
- 2000-12-21 US US09/740,876 patent/USRE37933E1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
SI9620059A (sl)	1998-06-30
EP0817791A4 (fr)	1998-07-15
HUP9801767A2 (hu)	1998-10-28
CA2216878A1 (fr)	1996-10-03
WO1996030385A1 (fr)	1996-10-03
CN1190402A (zh)	1998-08-12
FR2732357B1 (fr)	1997-04-30
EP0817791A1 (fr)	1998-01-14
BR9608449A (pt)	1999-11-30
AP1011A (en)	2001-09-22
AU701345B2 (en)	1999-01-28
HUP9801767A3 (en)	1999-04-28
AU5531596A (en)	1996-10-16
MX9707549A (es)	1998-07-31
USRE37933E1 (en)	2002-12-10
CZ308897A3 (cs)	1998-03-18
AP9701117A0 (en)	1996-03-28
FR2732357A1 (fr)	1996-10-04
OA10516A (en)	2002-04-22
KR19980703454A (ko)	1998-11-05
US5851521A (en)	1998-12-22
JPH11503314A (ja)	1999-03-26

Publication	Publication Date	Title
SK132797A3 (en)	1998-07-08	Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
Smith	1995	Viral vectors in gene therapy
AU738651B2 (en)	2001-09-20	Promoter for smooth muscle cell expression
JPH11511980A (ja)	1999-10-19	Ｍｄｍ２タンパク質の腫瘍原活性のアンタゴニスト及び癌治療におけるその使用
EP0752002A1 (fr)	1997-01-08	Inhibition de la proliferation arterielle des cellules des muscles lisses
EP0938553B1 (fr)	2009-08-05	Adn codant dp-75 et procede d'utilisation
CN100357433C (zh)	2007-12-26	可用于基因治疗和治疗性筛选的eNOS突变
US7329741B2 (en)	2008-02-12	Polynucleotides that hybridize to DP-75 and their use
KR100336551B1 (ko)	2002-05-11	망막아종 단백질의 조직 특이적 발현
JPH11514881A (ja)	1999-12-21	Ｇａｘタンパク質の癌治療への応用
US11952599B2 (en)	2024-04-09	Single adeno-associated virus (AAV)-sized nucleotide for use in CRISPR interference or activation
WO1996015245A1 (fr)	1996-05-23	Procede d'inhibition de la proliferation cellulaire pathologique non neoplasique
SK51199A3 (en)	2000-04-10	Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use
MXPA04011944A (es)	2005-03-31	Secuencias de control del gen corin humano.
KR19990022193A (ko)	1999-03-25	델타 피62, 이의 변이체, 핵산 서열 및 용도
MXPA97007549A (en)	1998-11-09	Viral vectors and their use to treat disordershiperproliferativos, in particular resteno
US7169764B1 (en)	2007-01-30	Promoter for smooth muscle cell expression
US7541343B2 (en)	2009-06-02	Inhibiting cellular proliferation by expressing yin yang-1
AU2002308413B2 (en)	2007-08-30	Yin yang 1
WO1996029423A1 (fr)	1996-09-26	Compositions et methodes pour induire une infection par des vecteurs retroviraux en dehors de leur gamme d'hotes
HK1018066A (en)	1999-12-10	Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
AU2002308413A1 (en)	2003-05-08	Yin yang 1